HRP20210847T1 - Supstituirani derivati indola kao inhibitori replikacije denga virusa - Google Patents
Supstituirani derivati indola kao inhibitori replikacije denga virusa Download PDFInfo
- Publication number
- HRP20210847T1 HRP20210847T1 HRP20210847TT HRP20210847T HRP20210847T1 HR P20210847 T1 HRP20210847 T1 HR P20210847T1 HR P20210847T T HRP20210847T T HR P20210847TT HR P20210847 T HRP20210847 T HR P20210847T HR P20210847 T1 HRP20210847 T1 HR P20210847T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- image
- pharmaceutically acceptable
- solvate
- polymorph
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title claims 5
- 206010012310 Dengue fever Diseases 0.000 title claims 5
- 208000025729 dengue disease Diseases 0.000 title claims 5
- 229940123627 Viral replication inhibitor Drugs 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 241000725619 Dengue virus Species 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (15)
1. Spoj s formulom (Ia) ili (Ib)
[image]
stereoizomerni oblik, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf; navedeni spoj je odabran iz skupine pri čemu:
R1 je CF3 ili OCF3, R2 je H ili OCH3 ili F, R3 je H;
i kada R2 je H tada R3 može također biti CH3.
2. Spoj ili njegov stereoizomerni oblik, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 naznačen time što navedeni spoj je odabran iz skupine koju čine:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
3. Farmaceutski pripravak naznačen time što sadrži spoj s formulom (Ia) ili (Ib) ili stereoizomerni oblik, ili njihova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 ili 2 zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili nosača.
4. Spoj s formulom (Ia) ili (Ib) ili stereoizomerni oblik, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 ili farmaceutski pripravak prema patentnom zahtjevu 3 naznačen time što se koristi kao lijek.
5. Spoj s formulom (Ia) ili (Ib) ili stereoizomerni oblik, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 ili farmaceutski pripravak prema patentnom zahtjevu 3 naznačen time što se koristi u liječenju denga groznice.
6. Spoj s formulom (Ia) ili (Ib) ili stereoizomerni oblik, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema patentnom zahtjevu 1 naznačen time što je za uporabu u inhibiciji replikacije denga virusa u biološkom uzorku ili pacijentu.
7. Spoj za uporabu prema patentnom zahtjevu 6 naznačen time što se nadalje obuhvaća istodobnu primjenu dodatnog terapijskog sredstva.
8. Spoj za uporabu prema patentnom zahtjevu 7 naznačen time što je navedeno dodatno terapijsko sredstvo odabrano od antivirusnog sredstva ili cjepiva protiv denga groznice, ili oboje.
9. Spoj prema patentnom zahtjevu 1 naznačen time što se spoj bira između
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njihove farmaceutski prihvatljive soli, solvata ili polimorfa.
10. Farmaceutski pripravak naznačen time što sadrži spoj prema patentnom zahtjevu 9, ili njegovu farmaceutski prihvatljivu sol, solvat ili polimorf zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili nosača.
11. Spoj prema patentnom zahtjevu 9, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf ili farmaceutski pripravak prema patentnom zahtjevu 10 naznačen time što se koristi kao lijek.
12. Spoj prema patentnom zahtjevu 9, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf ili farmaceutski pripravak prema patentnom zahtjevu 10 naznačen time što je za uporabu u liječenju denga groznice.
13. Spoj kao što je predstavljen bilo kojom strukturnom formulom iz patentnog zahtjeva 9, ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf naznačen time što je za uporabu u inhibiciji replikacije denga virusa u biološkom uzorku ili pacijentu.
14. Spoj za uporabu prema patentnom zahtjevu 13 naznačen time što se nadalje obuhvaća istodobnu primjenu dodatnog terapijskog sredstva.
15. Spoj za uporabu prema patentnom zahtjevu 14 naznačen time što je navedeno dodatno terapijsko sredstvo odabrano od antivirusnog sredstva ili cjepiva protiv denga groznice, ili oboje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163312 | 2016-03-31 | ||
| PCT/EP2017/057660 WO2017167950A1 (en) | 2016-03-31 | 2017-03-31 | Substituted indole derivatives as dengue viral replication inhibitors |
| EP17714750.1A EP3436435B1 (en) | 2016-03-31 | 2017-03-31 | Substituted indole derivatives as dengue viral replication inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210847T1 true HRP20210847T1 (hr) | 2021-07-23 |
Family
ID=55650292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210847TT HRP20210847T1 (hr) | 2016-03-31 | 2021-05-27 | Supstituirani derivati indola kao inhibitori replikacije denga virusa |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10646469B2 (hr) |
| EP (1) | EP3436435B1 (hr) |
| JP (1) | JP6888021B2 (hr) |
| KR (1) | KR102359743B1 (hr) |
| CN (1) | CN108884033B (hr) |
| AU (1) | AU2017242893A1 (hr) |
| BR (1) | BR112018068676A2 (hr) |
| CA (1) | CA3013405A1 (hr) |
| CL (1) | CL2018002729A1 (hr) |
| CO (1) | CO2018009559A2 (hr) |
| CR (1) | CR20180495A (hr) |
| DK (1) | DK3436435T3 (hr) |
| EA (1) | EA201892214A1 (hr) |
| EC (1) | ECSP18073245A (hr) |
| ES (1) | ES2882488T3 (hr) |
| HK (1) | HK1258142A1 (hr) |
| HR (1) | HRP20210847T1 (hr) |
| HU (1) | HUE054936T2 (hr) |
| IL (1) | IL261944A (hr) |
| LT (1) | LT3436435T (hr) |
| MX (1) | MX2018011784A (hr) |
| PH (1) | PH12018502015A1 (hr) |
| SG (1) | SG11201808138YA (hr) |
| SI (1) | SI3436435T1 (hr) |
| WO (1) | WO2017167950A1 (hr) |
| ZA (1) | ZA201806473B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
| WO2017167953A1 (en) * | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| WO2003050295A2 (en) | 2001-12-12 | 2003-06-19 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating hsp90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| JP2008526980A (ja) | 2005-01-14 | 2008-07-24 | ジェネラブズ テクノロジーズ インコーポレーティッド | ウイルス感染症を治療するためのインドール誘導体 |
| US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| CA2726985A1 (en) | 2008-06-03 | 2009-12-10 | Siga Technologies, Inc. | Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| US8143259B2 (en) | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
| WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| PT2523951E (pt) | 2010-01-15 | 2015-09-14 | Gilead Sciences Inc | Inibidores de vírus flaviviridae |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| JP6464176B2 (ja) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| ME03344B (me) | 2014-10-01 | 2019-10-20 | Janssen Pharmaceuticals Inc | Mono- ili di-supstituisani indoli kao inнibitori replikacije denga virusa |
| NO2721243T3 (hr) | 2014-10-01 | 2018-10-20 | ||
| SG11201702463YA (en) | 2014-10-01 | 2017-04-27 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20150335B1 (ar) | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3370698B1 (en) | 2015-11-03 | 2022-01-26 | Zoetis Services LLC | Sol-gel polymer composites and uses thereof |
| BR112018068538B1 (pt) | 2016-03-31 | 2023-12-12 | Takeda Pharmaceutical Company Limited | Composto, medicamento, e, uso de um composto |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
| UA123912C2 (uk) | 2016-04-01 | 2021-06-23 | Басф Се | Біциклічні сполуки |
| TW202313671A (zh) | 2016-04-01 | 2023-04-01 | 美商凱特製藥公司 | 嵌合抗原和ｔ細胞受體及使用方法 |
| EA039392B1 (ru) | 2016-04-01 | 2022-01-21 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способ лечения рака с применением замещенного аминопуринового соединения |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| CN113150170A (zh) | 2016-04-01 | 2021-07-23 | 凯德药业股份有限公司 | 嵌合受体及其方法和用途 |
| IL296966A (en) | 2016-04-01 | 2022-12-01 | Amgen Inc | Chimeric flt-3 receptors and methods of using them |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
-
2017
- 2017-03-31 MX MX2018011784A patent/MX2018011784A/es unknown
- 2017-03-31 WO PCT/EP2017/057660 patent/WO2017167950A1/en active Application Filing
- 2017-03-31 BR BR112018068676A patent/BR112018068676A2/pt not_active Application Discontinuation
- 2017-03-31 SI SI201730800T patent/SI3436435T1/sl unknown
- 2017-03-31 LT LTEP17714750.1T patent/LT3436435T/lt unknown
- 2017-03-31 CR CR20180495A patent/CR20180495A/es unknown
- 2017-03-31 ES ES17714750T patent/ES2882488T3/es active Active
- 2017-03-31 EA EA201892214A patent/EA201892214A1/ru unknown
- 2017-03-31 CN CN201780021395.5A patent/CN108884033B/zh active Active
- 2017-03-31 JP JP2018549441A patent/JP6888021B2/ja active Active
- 2017-03-31 CO CONC2018/0009559A patent/CO2018009559A2/es unknown
- 2017-03-31 HU HUE17714750A patent/HUE054936T2/hu unknown
- 2017-03-31 EP EP17714750.1A patent/EP3436435B1/en active Active
- 2017-03-31 US US16/087,800 patent/US10646469B2/en active Active
- 2017-03-31 SG SG11201808138YA patent/SG11201808138YA/en unknown
- 2017-03-31 AU AU2017242893A patent/AU2017242893A1/en not_active Abandoned
- 2017-03-31 DK DK17714750.1T patent/DK3436435T3/da active
- 2017-03-31 CA CA3013405A patent/CA3013405A1/en not_active Abandoned
- 2017-03-31 KR KR1020187027072A patent/KR102359743B1/ko active IP Right Grant
-
2018
- 2018-09-20 PH PH12018502015A patent/PH12018502015A1/en unknown
- 2018-09-26 IL IL261944A patent/IL261944A/en unknown
- 2018-09-26 CL CL2018002729A patent/CL2018002729A1/es unknown
- 2018-09-28 ZA ZA2018/06473A patent/ZA201806473B/en unknown
- 2018-09-28 EC ECSENADI201873245A patent/ECSP18073245A/es unknown
-
2019
- 2019-01-14 HK HK19100496.8A patent/HK1258142A1/zh unknown
-
2021
- 2021-05-27 HR HRP20210847TT patent/HRP20210847T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3436435A1 (en) | 2019-02-06 |
| US20190274999A1 (en) | 2019-09-12 |
| CO2018009559A2 (es) | 2018-09-20 |
| SI3436435T1 (sl) | 2021-08-31 |
| ECSP18073245A (es) | 2018-10-31 |
| DK3436435T3 (da) | 2021-08-09 |
| KR102359743B1 (ko) | 2022-02-07 |
| EA201892214A1 (ru) | 2019-03-29 |
| JP6888021B2 (ja) | 2021-06-16 |
| CA3013405A1 (en) | 2017-10-05 |
| PH12018502015A1 (en) | 2019-07-15 |
| HK1258142A1 (zh) | 2019-11-08 |
| LT3436435T (lt) | 2021-08-25 |
| IL261944A (en) | 2018-10-31 |
| ES2882488T3 (es) | 2021-12-02 |
| HUE054936T2 (hu) | 2021-10-28 |
| MX2018011784A (es) | 2019-02-13 |
| WO2017167950A1 (en) | 2017-10-05 |
| CN108884033B (zh) | 2021-03-09 |
| CL2018002729A1 (es) | 2018-11-23 |
| SG11201808138YA (en) | 2018-10-30 |
| CN108884033A (zh) | 2018-11-23 |
| US10646469B2 (en) | 2020-05-12 |
| KR20180130498A (ko) | 2018-12-07 |
| AU2017242893A1 (en) | 2018-08-09 |
| BR112018068676A2 (pt) | 2019-01-15 |
| JP2019510024A (ja) | 2019-04-11 |
| EP3436435B1 (en) | 2021-05-12 |
| CR20180495A (es) | 2018-12-06 |
| ZA201806473B (en) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20210942T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| HRP20211782T1 (hr) | Derivati indola kao inhibitori replikacije denga virusa | |
| JP2019509276A5 (hr) | ||
| HRP20210675T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| CL2020002866A1 (es) | Compuestos de heteroaril tetracíclicos | |
| JP2017531619A5 (hr) | ||
| AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
| HRP20211102T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
| HRP20201023T1 (hr) | Dioksilan analozi uridina za liječenje raka | |
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
| JP2019510027A5 (hr) | ||
| JP2019510034A5 (hr) | ||
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20211352T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes |